177 related articles for article (PubMed ID: 17618725)
1. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
2. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
3. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
4. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
5. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
6. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
Szotáková B; Skálová L; Wsól V; Kvasniècková E
J Pharm Pharmacol; 2000 May; 52(5):495-500. PubMed ID: 10864136
[TBL] [Abstract][Full Text] [Related]
10. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
11. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway.
Jin Y; Mesaros AC; Blair IA; Penning TM
Biochem J; 2011 Jul; 437(1):53-61. PubMed ID: 21521174
[TBL] [Abstract][Full Text] [Related]
13. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand.
Skarydová L; Andrýs R; Holubová L; Stambergová H; Kňavová J; Wsól V; Bílková Z
J Sep Sci; 2013 Apr; 36(7):1176-84. PubMed ID: 23495195
[TBL] [Abstract][Full Text] [Related]
14. Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol.
Atalla A; Breyer-Pfaff U; Maser E
Xenobiotica; 2000 Aug; 30(8):755-69. PubMed ID: 11037109
[TBL] [Abstract][Full Text] [Related]
15. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
16. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.
Steckelbroeck S; Jin Y; Oyesanmi B; Kloosterboer HJ; Penning TM
Mol Pharmacol; 2004 Dec; 66(6):1702-11. PubMed ID: 15383625
[TBL] [Abstract][Full Text] [Related]
17. High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver.
Breyer-Pfaff U; Nill K
Biochem Pharmacol; 2000 Feb; 59(3):249-60. PubMed ID: 10609553
[TBL] [Abstract][Full Text] [Related]
18. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
19. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
20. Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver.
Breyer-Pfaff U; Martin HJ; Ernst M; Maser E
Drug Metab Dispos; 2004 Sep; 32(9):915-22. PubMed ID: 15319331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
